Skip to main content

and
  1. Article

    Open Access

    Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

    Afatinib, a second-generation epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan in 2014. This study evaluated clinical...

    Hisashi Tanaka, Kageaki Taima, Masamichi Itoga, Yoshiko Ishioka in Medical Oncology (2019)

  2. Article

    Open Access

    A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

    This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring...

    Hisashi Tanaka, Kageaki Taima, Yoshihito Tanaka, Masamichi Itoga in Medical Oncology (2018)

  3. No Access

    Article

    Polyinosinic-Polycytidylic Acid Induces the Expression of GRO-α in BEAS-2B Cells

    Growth-related oncogene protein-α (GRO-α)/CXCLl is a chemokine that activates neutrophils and plays an important role in inflammatory reactions. Polyinosinic-polycytidylic acid (poly IC) is a synthetic double-...

    Koji Yamashita, Tadaatsu Imaizumi, Kageaki Taima, Takashi Fujita in Inflammation (2005)

  4. No Access

    Article

    Effect of Double-Stranded RNA on the Expression of Epithelial Neutrophil Activating Peptide-78/CXCL-5 in Human Endothelial Cells

    Epithelial neutophil activating peptide-78 (ENA-78)/CXCL-5 is a member of CXC chemokines. ENA-78 was originally described as a factor produced by epithelial cells only. But other types of cells including vascu...

    Tadaatsu Imaizumi, Masaharu Hatakeyama, Kageaki Taima, Akira Ishikawa in Inflammation (2004)